Seeking Alpha

Rosetta Genomics (ROSG +15.6%) continues its volatile trajectory, jumping higher today after...

Rosetta Genomics (ROSG +15.6%) continues its volatile trajectory, jumping higher today after announcing that data from studies of miRview mets2 in patients with cancer were published online in The Oncologist. The study demonstrated the ability of the miRview mets2 assay to identify 42 tumor types with high accuracy.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|